Can patients with kidney cancer take Anamorelin?

Anamorelin is a novel, oral, selective ghrelin receptor agonist. Its main function is to improve the weight loss and loss of appetite in patients with cancer cachexia by simulating the ghrelin secreted by the gastrointestinal tract. Currently, anamorelin has been approved in Japan for the treatment of cancer cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, colorectal cancer and other malignant tumors.

Although kidney cancer is not specifically listed among the indications for anamorelin, this does not mean that patients with kidney cancer cannot use anamorelin. In practical applications, doctors may decide whether to use anamorelin based on the patient's specific conditions, such as the presence of cachexia symptoms, nutritional status, etc. Therefore, for patients with kidney cancer, if symptoms of cachexia occur and the doctor believes that anamorelin may be beneficial, then the use of anamorelin may be considered.

Before using anamorelin, you need to know whether there are any contraindications. For example, patients with a history of hypersensitivity to anamorelin components, patients with congestive heart failure, patients with myocardial infarction or angina pectoris should avoid using anamorelin. Anamorelin may cause some side effects, such as weakness, fatigue, atrial fibrillation, etc. During use, you need to pay close attention to these side effects and report them to your doctor in time. Anamorelin is usually recommended for adults to take 100 mg orally once a day on an empty stomach. In order to prevent diet from affecting the absorption of the drug, it is recommended not to eat within 1 hour after taking the drug.